Comment on “Drug survival analysis is not a good method for assessing the safety or effectiveness of systemic therapies in psoriasis”-Reference-Cited by-同舟云学术

Comment on “Drug survival analysis is not a good method for assessing the safety or effectiveness of systemic therapies in psoriasis”

Published:2017-09 Issue:7 Volume:108 Page:695-696
ISSN:0001-7310
Container-title:Actas Dermo-Sifiliográficas
language:en
Short-container-title:Actas Dermo-Sifiliográficas

Author:

van den Reek J.M.P.A.,Kievit W.,de Jong E.M.G.J.

Publisher

Elsevier BV

Reference7 articles.

1. Drug survival analysis is not a good method for assessing the safety or effectiveness of systemic therapies in psoriasis;Davila-Seijo;Actas Dermosifiliogr,2017

2. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor alpha inhibitor therapy: results from the Danish Nationwide DANBIO Registry;Glintborg;Arthritis Rheum,2013

3. Drug survival studies in dermatology:principles purposes, and pitfalls;van den Reek;J Invest Dermatol,2015

4. ‘Happy’ drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network;van den Reek;Br J Dermatol,2014

5. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR);Warren;J Invest Dermatol,2015

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multinational Drug Survival Study of Omalizumab in Patients With Chronic Urticaria and Potential Predictors for Discontinuation;JAMA Dermatology;2024-09-01

2. Durability and long-term outcomes of biologic therapies in psoriasis;Expert Review of Clinical Immunology;2023-08-25

3. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA;Dermatology and Therapy;2023-03-16

4. Treatment patterns in older patients with myelodysplastic syndromes: A population-based analysis reflecting the real world;Journal of Geriatric Oncology;2023-03

5. Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study;American Journal of Clinical Dermatology;2021-03-30